Nuklearmedizin-nuclear Medicine最新文献

{"title":"DGN-Summer School 2023","authors":"","doi":"10.1055/a-2040-9453","DOIUrl":"https://doi.org/10.1055/a-2040-9453","url":null,"abstract":"Wir freuen uns, nach einer 3-jährigen „Corona-Pause“ in diesem Jahr vom 24.-26. August 2023 die DGN-Summer School wieder an der Charité in Berlin zum Thema „Translational Research in Molecular Imaging and Radionuclide Therapy“ durchzuführen. Die wissenschaftliche Leitung liegt erneut bei Prof. Dr. Winfried Brenner, Berlin (D), Prof. Dr. Martin Gotthardt, Nijmegen (NL), und Prof. Dr. Felix M. Mottaghy, Aachen und Maastricht (NL).","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"275 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136121894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intraindividual Comparison of Physiologic [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 Uptake in Ganglia in Patients with Prostate Cancer: a retrospective, monocentric analysis","authors":"E. Novruzov, D. Schmitt, K. Mattes-György, M. Beu, J. M. Henke, C. Antke, J. Cardinale, G. Niegisch, L. Schimmöller, F. L. Giesel, E. Mamlins","doi":"10.1055/s-0043-1766379","DOIUrl":"https://doi.org/10.1055/s-0043-1766379","url":null,"abstract":"Ziel/Aim Several studies indicate a relatively high rate of detection of benign findings, in particular ganglia, in PSMA PET imaging. To date, no studies have directly compared [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 ganglionic uptake intraindividually and analyzed the different detection rates and underlying molecular and physical mechanisms. With this monocentric retrospective study, we sought to evaluate the intraindividual physiological ganglion uptake of different PSMA ligands.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135419771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of tumor volume assessment on PSMA PET after [Lu-177]PSMA radioligand therapy evaluated by PSMA PET/CT consensus statement and RECIP 1.0","authors":"F. Kind, A. C. Eder, C. A. Jilg, P. E. Hartrampf, P. T. Meyer, J. Ruf, K. Michalski","doi":"10.1055/s-0043-1766156","DOIUrl":"https://doi.org/10.1055/s-0043-1766156","url":null,"abstract":"Ziel/Aim Quantitative assessments of positron emission tomography/computer tomography targeting the prostate specific membrane antigen (PSMA PET/CT) are promising for the evaluation of response to [Lu-177]PSMA radioligand therapy (PSMA RLT). Both the updated PSMA PET/CT consensus statement (CS) [1] as well as the recently introduced Response Evaluation Criteria In PSMA-PET/CT (RECIP 1.0) [2], strongly emphasize the change in whole-body tumor volume as a major response criterion. PSMATV50 [3], based on a 50% threshold of the lesional maximum standardized uptake value, appears to be a promising parameter for whole-body tumor volume determination. In the present study PSMATV50 was used for both CS and RECIP 1.0 in order to assess their predictive value for overall survival (OS).","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"46 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136002535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peptide Receptor Radionuclide Therapy in Patients with Advanced Progressive Medullary Thyroid Cancer: Efficacy, Safety and Survival Predictors","authors":"Q. X. Liu, H. R. Kulkarni, T. Z. Zhao, C. Schuchardt, X. Chen, Z. H. Zhu, J. Zhang, R. P. Baum","doi":"10.1055/s-0043-1766219","DOIUrl":"https://doi.org/10.1055/s-0043-1766219","url":null,"abstract":"Ziel/Aim Metastatic medullary thyroid carcinoma (MTC) is often has a rapid disease progression and poor prognosis with few therapeutic options available. Peptide Receptor Radionuclide Therapy (PRRT) has demonstrated success in the management of gastroenteropancreatic neuroendocrine tumors and has also been used to treat MTC. The objective of this study was to assess the safety and efficacy of PRRT in patients with advanced, progressive MTC, to determine survival and potential predictors of survival.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"16 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135419776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Voxel-based dosimetry predicts hepatotoxicity in hepatocellular carcinoma patients undergoing radioembolization with 90Y glass microspheres","authors":"M. Watanabe, H. Grafe, J. Theysohn, B. Schaarschmidt, J. Ludwig, L. Jochheim, M. Jeschke, H. Schmidt, W. P. Fendler, A. Moraitis, K. Herrmann, K. L. Pomykala, M. Weber","doi":"10.1055/s-0043-1766312","DOIUrl":"https://doi.org/10.1055/s-0043-1766312","url":null,"abstract":"Ziel/Aim Personalized dosimetry holds promise to improve radioembolization treatment outcomes in hepatocellular carcinoma (HCC) patients. To this end, tolerance doses for healthy liver tissue (HLT) are assessed by calculating the mean whole-liver normal tissue dose (WLNT), which neglects non-uniform dose distribution. Thus, we analyzed whether voxel-based dosimetry could be more accurate in predicting hepatotoxicity in HCC patients undergoing radioembolization.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"61 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135419769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Personalia","authors":"","doi":"10.1055/a-2040-9488","DOIUrl":"https://doi.org/10.1055/a-2040-9488","url":null,"abstract":"PD Dr. Christoph Rischpler ([Abb. 1]) ist seit Januar 2023 neuer Ärztlicher Direktor der Klinik für Nuklearmedizin im Klinikum Stuttgart. Er war zuletzt kommissarischer Leiter der Nuklearmedizin im Evangelischen Bethesda-Krankenhaus zu Duisburg sowie W2-Professor für nuklearkardiologische Bildgebung am Universitätsklinikum Essen. Sein Medizinstudium hat der Facharzt für Nuklearmedizin unter anderem in München, San Francisco und Sydney absolviert. Am Klinikum Stuttgart möchte Christoph Rischpler die nuklearkardiologische Bildgebung und neue Therapien wie die PSMA-Radioligandentherapie und die Peptid-Radiorezeptortherapie stärken. Dazu strebt er die Zertifizierung der Klinik als nuklearkardiologisches Zentrum an.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"51 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136121604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bestimmung der Aktivitätskonzentration von Nuklidgemischen von I-131 und Lu-177m/Lu-177 im Abwasser einer nuklearmedizinischen Therapiestation. Methode 1","authors":"D. Kupitz, E. Einspänner, H. Wissel, A. Hohn, M. C. Kreissl, O. S. Grosser","doi":"10.1055/s-0043-1766289","DOIUrl":"https://doi.org/10.1055/s-0043-1766289","url":null,"abstract":"Ziel/Aim Für die Freigabe radioaktiver Stoffe lt. StrlSchV ist die Quantifizierung der vorliegenden Nuklide erforderlich. Hierfür wurden zwei Methoden für die Analyse von Nuklidgemischen (I-131 und Lu-177m/Lu-177) untersucht. In der hier vorgestellten Methode werden die Energiespektren einer Probe zu zwei Zeitpunkten gemessen und die spezifischen Aktivitätskonzentrationen (AKs) der vorhandenen Nuklide ermittelt. Ein typisches Nutzungsszenario ist die Freigabe von Abwässern aus einer Abwasserschutzanlage.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"149 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135419770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radioiodine ablation of thyroid remnants in patients with Graves’ orbitopathy","authors":"M. Weber, J. Koenen, N. Bechrakis, M. Stöhr, K. Herrmann, W. P. Fendler, A. Eckstein, M. Oeverhaus","doi":"10.1055/s-0043-1766224","DOIUrl":"https://doi.org/10.1055/s-0043-1766224","url":null,"abstract":"Ziel/Aim To assess response following ablation of thyroid remnants (ATR) with radioactive iodine therapy (RAIT) in patients with unstable Graves’ orbitopathy (GO) after (subtotal) thyroidectomy.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"39 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135419772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adverse events unlikely after fine-needle aspiration biopsies of thyroid nodules in patients on low-dose aspirin: a prospective controlled systematic single center analysis.","authors":"Michael Cordes,&nbsp;Theresa Ida Götz,&nbsp;Torsten Kuwert,&nbsp;Christian Schmidkonz","doi":"10.1055/a-1972-9372","DOIUrl":"https://doi.org/10.1055/a-1972-9372","url":null,"abstract":"<p><strong>Aim: </strong>Our aim was to test the assertion that in terms of rate or severity level, adverse events (AEs) after fine-needle aspiration biopsies (FNABs) of thyroid nodules are unfazed by daily low-dose (100 mg) aspirin (acetylsalicylic acid, ASA) intake.</p><p><strong>Methods: </strong>We selected 268 patients for study, grouped as ASA-treated (P_ASA, n=78) or control (P_Ctrl, n=190) subjects. Controls received no antithrombotic medication. AE rates and severities were then analyzed based on patient- and nodule-related factors. We also compared group rates of non-diagnostic cytology results.</p><p><strong>Results: </strong>AEs arising after FNABs (P_ASA, 5%; P_Ctrl, 8%) did not differ significantly by group in rate (<i>p</i>=0.4873) or severity level (<i>p</i>=0.3399). All were classifiable as minor incidents, none warranting any intervention.</p><p><strong>Conclusions: </strong>The data from the present study suggest, AEs after FNABs of thyroid nodules seldom occur and qualify as minor incidents. Such procedures may be safely conducted in patients taking daily low-dose ASA. There is no evidence to support preemptive therapeutic withdrawal.</p>","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"62 1","pages":"34-37"},"PeriodicalIF":1.5,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9220502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Procedure Guideline for Prostate Cancer Imaging with PSMA-ligand PET/CT].","authors":"Ali Afshar-Oromieh,&nbsp;Matthias Eiber,&nbsp;Wolfgang Fendler,&nbsp;Matthias Schmidt,&nbsp;Kambiz Rahbar,&nbsp;Hojjat Ahmadzadehfar,&nbsp;Lale Umutlu,&nbsp;Boris Hadaschik,&nbsp;Oliver W Hakenberg,&nbsp;Paolo Fornara,&nbsp;Jens Kurth,&nbsp;O Neels,&nbsp;Hans-Jürgen Wester,&nbsp;Markus Schwaiger,&nbsp;Klaus Kopka,&nbsp;Uwe Haberkorn,&nbsp;Ken Herrmann,&nbsp;Bernd J Krause","doi":"10.1055/a-1984-8167","DOIUrl":"https://doi.org/10.1055/a-1984-8167","url":null,"abstract":"<p><p>PSMA-PET/CT for imaging prostate cancer (PC) has spread worldwide since its clinical introduction in 2011. The majority of experiences have been collected for PSMA-PET-imaging of recurrent PC. Data for primary staging of high-risk PC are highly promising. Meanwhile, a plethora of PSMA-ligands are available for clinical use (e. g. ⁶⁸Ga-PSMA-11, ⁶⁸Ga-PSMA-I&T, ⁶⁸Ga-PSMA-617, ¹⁸F-DCFBC, ¹⁸F-DCFPyL, ¹⁸F-PSMA-1007, ¹⁸F-rhPSMA-7 and ¹⁸F-JK-PSMA-7). However, an official approval is available only for ⁶⁸Ga-PSMA-11 (approved by the US FDA in 2020) and ¹⁸F-DCFPyL (approved by the US FDA in 2021).Recommendations for acquisition times vary from 1-2 h p. i. It has been shown that for the majority of tumour lesions, the contrast in PSMA-PET/CT increases with time. Therefore, additional late imaging can help to clarify unclear findings. PSMA-PET/CT should be performed prior to commencing an androgen deprivation therapy (ADT) since (long term) ADT reduces the visibility of PC lesions. Following injection of PSMA-ligands, hydration and forced diuresis are recommended for PSMA-ligands with primarily excretion via the kidneys in order to increase the visibility of tumour lesions adjacent to the urinary bladder.PSMA-ligands are physiologically taken up in multiple normal organs. For some ¹⁸F-labelled PSMA-ligands, presence of unspecific focal bone uptake has been reported. When using these tracers, focal bone uptake without CT-correlate should be interpreted with great caution. Besides prostate cancer, practically all solid tumors express PSMA in their neovasculature thereby taking up PSMA-ligands, although usually at a lower extent compared to PC. Also multiple benign lesions and inflammatory processes (e. g. lymph nodes) take up PSMA-ligands, also usually at lower extent compared to PC.</p>","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"62 1","pages":"5-19"},"PeriodicalIF":1.5,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10667811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}